Upregulation of IGF-I and IGF-IR in HBV-HCC cell lines with inflamed-CM treatment.
2016-02-26T08:27:33Z (GMT) by
<p>mRNA levels of <i>IGF-I</i> and <i>IGF-IR</i> in human HCC cell lines of HepG2.2.15, Hep3B, PLC5 (HBV<sup>+</sup>HBsAg<sup>+</sup>), HA22T (HBV<sup>+</sup>HBsAg<sup>−</sup>), HepG2, and Huh7 (HBV<sup>−</sup>HBsAg<sup>−</sup>) with inflamed-CM treatment for 7 days (by quantitative real-time RT-PCR). The dashed line indicates the gene expression in HCC cells without inflamed-CM treatment (multiple of expression = 1, control group). <b>(B)</b> IGF-IR levels in HCC cells with and without inflamed-CM treatment (by Western blotting). <b>(C)</b> Effect of inflamed-CM on the activation of IGF-IR/Akt signaling in HBV<sup>+</sup>HBsAg<sup>+</sup> HepG2.2.15 and Hep3B is shown. <b>(D)</b> Effect of IGF-IR phosphorylation inhibitor PPP on inflamed-CM-induced IGF-IR/Akt signaling activation is shown. Effect of PPP (1 μM) on inflamed-CM-induced mRNA levels of <i>OCT4</i> <b>(E)</b> and <i>NANOG</i> <b>(F)</b> in HepG2.2.15 and Hep3B cells is shown. **<i>P</i> < .01, ***<i>P</i> < .001, by <i>t</i>-test.</p>